Loading...
•
Mar 31, 2023
Soleno Therapeutics Q1 2023 Earnings Report
Soleno Therapeutics reported financial results for Q1 2023 and provided a corporate update.
Key Takeaways
Soleno Therapeutics reported a net loss of $8.4 million for the first quarter of 2023. The company's research and development efforts are primarily focused on advancing its lead product candidate, DCCR, for the treatment of PWS.
Completed enrollment in the randomized withdrawal period of Study C602 for DCCR.
FDA acknowledged the study data's potential to support an NDA submission for DCCR.
Top-line data from Study C602 is expected in the third quarter of 2023.
Received $10 million following enrollment completion in Study C602.
Soleno Therapeutics
Soleno Therapeutics
Forward Guidance
Soleno believes that its current funds, including the recently received $10 million, are sufficient to fund operations through top-line data, which is anticipated in the third quarter of 2023.